Is Harmony Biosciences (HRMY) Pricing Reflect Recent Share Slump And DCF Upside Potential

Simply Wall St.02-24

If you are wondering whether Harmony Biosciences Holdings is attractively priced or misunderstood by the market, you are not alone. This article will walk through what the current share price really ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613765918?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-02-24 11:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613765918","market":"hk","top_or_hot":-1,"title":"Is Harmony Biosciences (HRMY) Pricing Reflect Recent Share Slump And DCF Upside Potential","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Harmony Biosciences Holdings is attractively priced or misunderstood by the market, you are not alone. This article will walk through what the current share price really ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/is-harmony-biosciences-hrmy-pricing-reflect-recent-share-slu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Harmony Biosciences (HRMY) Pricing Reflect Recent Share Slump And DCF Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Harmony Biosciences (HRMY) Pricing Reflect Recent Share Slump And DCF Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-24 11:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/is-harmony-biosciences-hrmy-pricing-reflect-recent-share-slu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Harmony Biosciences Holdings is attractively priced or misunderstood by the market, you are not alone. This article will walk through what the current share price really ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/is-harmony-biosciences-hrmy-pricing-reflect-recent-share-slu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/is-harmony-biosciences-hrmy-pricing-reflect-recent-share-slu","article_id":"2613765918","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/is-harmony-biosciences-hrmy-pricing-reflect-recent-share-slu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613765918","pubTimestamp":1771903536,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Harmony Biosciences Holdings is attractively priced or misunderstood by the market, you are not alone. This article will walk through what the current share price really implies.\nThe stock last closed at US$26.87, after declines of 25.4% over the past week, 27.0% over the past month, and 21.4% over the past year. These moves may have changed how investors view both its potential and its risks.\nRecent news coverage around Harmony Biosciences has focused on the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","HRMY":"Harmony Biosciences Holdings, Inc.","BK4007":"制药"},"translate_title":"Harmony Biosciences(HRMY)的定价是否反映了近期股价暴跌和DCF上涨潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1.5,"HRMY":1.5},"content_text":"If you are wondering whether Harmony Biosciences Holdings is attractively priced or misunderstood by the market, you are not alone. This article will walk through what the current share price really implies. The stock last closed at US$26.87, after declines of 25.4% over the past week, 27.0% over the past month, and 21.4% over the past year. These moves may have changed how investors view both its potential and its risks. Recent news coverage around Harmony Biosciences has focused on the business and its outlook rather than short term trading activity, giving investors more context for the share price moves. This kind of news can shift attention back to fundamentals, which is exactly what we will focus on next. Right now, Harmony Biosciences has a valuation score of 5/6, suggesting that on our six valuation checks it screens as undervalued on most measures. We will compare those methods before finishing with a broader way to think about what the valuation really means for long term investors.  Find out why Harmony Biosciences Holdings's -21.4% return over the last year is lagging behind its peers. AdvertisementApproach 1: Harmony Biosciences Holdings Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today using a required rate of return. For Harmony Biosciences Holdings, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest reported free cash flow is about $280.2 million. Analyst inputs and subsequent extrapolations suggest projected free cash flow of $561.5 million in 2030, with intermediate annual figures between 2026 and 2035 that are gradually higher over time. Simply Wall St uses analyst estimates for the first years, then extends those trends further out to build a 10 year path of cash flows. When these projected cash flows are discounted back and combined, the DCF model arrives at an estimated intrinsic value of about $290.00 per share. Compared with the recent share price of US$26.87, this suggests the stock appears roughly 90.7% undervalued on this metric alone. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Harmony Biosciences Holdings is undervalued by 90.7%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks. HRMY Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Harmony Biosciences Holdings. Approach 2: Harmony Biosciences Holdings Price vs Earnings For a profitable company like Harmony Biosciences Holdings, the P/E ratio is a useful shortcut because it connects what you pay for the stock to the earnings it is currently generating. Investors usually expect companies with stronger growth prospects and lower risk to support a higher, or more generous, P/E, while slower growth or higher risk typically calls for a lower, more conservative P/E. Harmony Biosciences currently trades on a P/E of 8.34x. That sits below both the Pharmaceuticals industry average of 19.56x and the broader peer group average of 26.76x. Simply Wall St also calculates a “Fair Ratio” for Harmony Biosciences of 18.46x, which is an estimate of what its P/E might be given its earnings growth profile, industry, profit margins, market cap and risk characteristics. This Fair Ratio is more tailored than a simple comparison with peers or the industry, because it adjusts for company specific traits rather than assuming all businesses deserve the same multiple. Setting the current P/E of 8.34x against the Fair Ratio of 18.46x suggests Harmony Biosciences is trading below the level implied by those fundamentals. Result: UNDERVALUED NasdaqGM:HRMY P/E Ratio as at Feb 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies. Upgrade Your Decision Making: Choose your Harmony Biosciences Holdings Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple tool on Simply Wall St's Community page that lets you attach your own story for Harmony Biosciences Holdings to the numbers such as fair value, and estimates for future revenue, earnings and margins. A Narrative links what you think is happening with the business, for example how important WAKIX, ZYN002 and the broader rare disease portfolio might be over time, to a forecast and then to a fair value that you can directly compare with the current share price to help with your own buy or sell decisions. Narratives on the platform are updated when new information appears in the market, such as the latest US$47.30 consensus fair value update or the analyst price targets that currently span from US$31.00 on the cautious side to US$70.00 on the optimistic side. This allows you to see in one place how different investors interpret the same data and decide which story best matches your own view on Harmony Biosciences Holdings. Do you think there's more to the story for Harmony Biosciences Holdings? Head over to our Community to see what others are saying! NasdaqGM:HRMY 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Harmony Biosciences Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613765918","isCrawlerRequest":true}